RT Journal Article
SR Electronic
T1 Cellular and molecular heterogeneities and signatures, and pathological trajectories of fatal COVID-19 lungs defined by spatial single-cell transcriptome analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.24.23286388
DO 10.1101/2023.02.24.23286388
A1 Das, Arun
A1 Meng, Wen
A1 Liu, Zhentao
A1 Hasib, Md Musaddaqul
A1 Galloway, Hugh
A1 Ramos da Silva, Suzane
A1 Chen, Luping
A1 Sica, Gabriel L
A1 Paniz-Mondolfi, Alberto
A1 Bryce, Clare
A1 Grimes, Zachary
A1 Sordillo, Emilia Mia
A1 Cordon-Cardo, Carlos
A1 Rivera, Karla Paniagua
A1 Flores, Mario
A1 Chiu, Yu-Chiao
A1 Huang, Yufei
A1 Gao, Shou-Jiang
YR 2023
UL http://medrxiv.org/content/early/2023/02/26/2023.02.24.23286388.abstract
AB Despite intensive studies during the last 3 years, the pathology and underlying molecular mechanism of coronavirus disease 2019 (COVID-19) remain poorly defined. Here, we examined postmortem COVID-19 lung tissues by spatial single-cell transcriptome analysis (SSCTA). We identified 18 major parenchymal and immune cell types, all of which are infected by SARS-CoV-2. Compared to the non-COVID-19 control, COVID-19 lungs have reduced alveolar cells (ACs), and increased innate and adaptive immune cells. Additionally, 19 differentially expressed genes in both infected and uninfected cells across the tissues mirror the altered cellular compositions. Spatial analysis of local infection rates revealed regions with high infection rates that are correlated with high cell densities (HIHD). The HIHD regions express high levels of SARS-CoV-2 entry-related factors including ACE2, FURIN, TMPRSS2, and NRP1, and co-localized with organizing pneumonia (OP) and lymphocytic and immune infiltration that have increased ACs and fibroblasts but decreased vascular endothelial cells and epithelial cells, echoing the tissue damage and wound healing processes. Sparse non- negative matrix factorization (SNMF) analysis of neighborhood cell type composition (NCTC) features identified 7 signatures that capture structure and immune niches in COVID-19 tissues. Trajectory inference based on immune niche signatures defined two pathological routes. Trajectory A progresses with primarily increased NK cells and granulocytes, likely reflecting the complication of microbial infections. Trajectory B is marked by increased HIHD and OP, possibly accounting for the increased immune infiltration. The OP regions are marked by high numbers of fibroblasts expressing extremely high levels of COL1A1 and COL1A2. Examination of single-cell RNA-seq data (scRNA-seq) from COVID-19 lung tissues and idiopathic pulmonary fibrosis (IPF) identified similar cell populations primarily consisting of myofibroblasts.Immunofluorescence staining revealed the activation of IL6-STAT3 and TGF-²-SMAD2/3 pathways in these cells, which likely mediate the upregulation of COL1A1 and COL1A2, and excessive fibrosis in the lung tissues. Together, this study provides an SSCTA atlas of cellular and molecular signatures of fatal COVID-19 lungs, revealing the complex spatial cellular heterogeneity, organization, and interactions that characterized the COVID-19 lung pathology.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe thank members of Drs. Shou-Jiang Gao and Yufei Huang laboratories for technical assistance and discussions. This study was supported by grants from the National Institutes of Health (CA096512 and CA124332 to S.-J. Gao), UPMC Hillman Cancer Center Startup Funds to S.-J. Gao and Y. Huang, and in part by award P30CA047904. This research was also supported in part by the University of Pittsburgh Center for Research Computing, RRID:SCR_022735, through the resources provided. Specifically, this work used the HTC cluster, which is supported by the National Institutes of Health (S10OD028483).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The University of Pittsburgh IRB determined that the study is not research involving human subjects as defined by DHHS and FDA regulations and waived of ethical oversight (STUDY20050085).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data supporting findings in this study including all the original spatial single-cell transcriptome data, segmented and filtered reads of all cells, and DAPI and H&E staining images will be deposited to Zenodo. The spatial single-cell transcriptome data will also be deposited in GEO.